Skyrizi and Rinvoq are expected to generate nearly $24 billion in combined sales in 2025, reflecting a $6 billion increase year-over-year. AbbVie raised its 2027 combined sales guidance for these ...

The decline was offset by sales of its newer arthritis drugs Skyrizi, which soared by 57% to $3.78 billion, and Rinvoq, which logged a 46% gain to $1.83 billion. Chief Executive Robert Michael ...

In particular, recently launched drugs Skyrizi and Rinvoq have shown improved efficacy over Humira and other currently leading treatment options, which should support combined annual sales of ...

Today, a brief rundown of news involving Novartis and AbbVie, as well as updates from Biogen, Merck & Co. and Sanofi that you may have missed. Pioneers like Alnylam Pharmaceuticals have led the RNA ...

The best things in life are free. Sign up for our email to enjoy your city without spending a thing (as well as some options when you’re feeling flush). Our newsletter hand-delivers the best ...

Of particular importance, very high-level responses, including 90 and 100% improvements in PASI (100% improvement is complete clearance of disease) were found in well over half of the study ...

The PASI 90 response rate was close to 80%, and the PASI 100 response rate exceeded 40%, all efficacy measures significantly superior to the placebo group. Over 80% of patients achieved a PASI 90 ...

The PASI 90 response rate was close to 80%, and the PASI 100 response rate exceeded 40%, all efficacy measures significantly superior to the placebo group. Over 80% of patients achieved a PASI 90 ...

100% of patients treated with 150 mg, 300 mg and 600 mg of QX004N achieved PASI 75 at week 12 and PASI ... shown results comparable to risankizumab (Skyrizi, AbbVie), an IL-23a inhibitor indicated ...

Rinvoq's total estimated spending came in about $40 million behind Skyrizi's total last year, according to iSpot.TV, while Dupixent's total was about $100 million lower than Skyrizi's. The same ...

Image credit: Skorzewiak / Shutterstock AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for ...